መነሻ › ስቴቶቲክ የጉበት በሽታ › North Carolina
በNorth Carolina ለስቴቶቲክ የጉበት በሽታ የሚደረጉ ክሊኒካዊ ጥናቶች
ለስቴቶቲክ የጉበት በሽታ የሚደረጉ 13 ጥናቶች በNorth Carolina ባሉ ቦታዎች ተሳታፊዎችን እየፈለጉ ነው።
በNorth Carolina ውስጥ ያሉ ከተሞች
Official study text (English)
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
- 89bio Clinical Study Site, Asheville
- 89bio Clinical Study Site, Charlotte
- 89bio Clinical Study Site, Durham
- እና 2 ተጨማሪ
ተሳታዮችን በመፈለግ ላይደረጃ 3
እድሜ ከ18 እስከ 75 · ሁሉም ጾታዎች · የተሻሻለው በ5 ኦክቶ 2026 · NCT06419374A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
- 89bio Clinical Study Site, Charlotte
- 89bio Clinical Study Site, Durham
- 89bio Clinical Study Site, Fayetteville
- እና 3 ተጨማሪ
ተሳታዮችን በመፈለግ ላይደረጃ 3
እድሜ ከ18 እስከ 80 · ሁሉም ጾታዎች · የተሻሻለው በ5 ኦክቶ 2026 · NCT06318169A Study to Investigate Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)
- GSK Investigational Site, Morehead City
ተሳታዮችን በመፈለግ ላይደረጃ 3
እድሜ ከ18 እስከ 75 · ሁሉም ጾታዎች · የተሻሻለው በ30 ሴፕቴ 2026 · NCT07704892Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States
- Duke Liver Center, Durham
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ ከ18 እስከ 75 · ሁሉም ጾታዎች · የተሻሻለው በ28 ሴፕቴ 2026 · NCT05832229A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
- Duke University - Main Hospital and Clinics, Durham
- Monroe Biomedical Research, Monroe
- Carteret Medical Group, Morehead City
ተሳታዮችን በመፈለግ ላይደረጃ 3
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ22 ሴፕቴ 2026 · NCT07165028A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
- Akero Clinical Study Site, Chapel Hill
- Akero Clinical Study Site, Charlotte
- Akero Clinical Study Site, Charlotte
- እና 5 ተጨማሪ
ተሳታዮችን በመፈለግ ላይደረጃ 3
እድሜ ከ18 እስከ 80 · ሁሉም ጾታዎች · የተሻሻለው በ21 ሴፕቴ 2026 · NCT06528314A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH
- GSK Investigational Site, Morehead City
ተሳታዮችን በመፈለግ ላይደረጃ 3
እድሜ ከ18 እስከ 75 · ሁሉም ጾታዎች · የተሻሻለው በ17 ሴፕቴ 2026 · NCT07221188A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)
- Coastal Research Institute, Fayetteville
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ ከ18 እስከ 75 · ሁሉም ጾታዎች · የተሻሻለው በ9 ሴፕቴ 2026 · NCT07288138A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 70 Years With Alcohol-related Liver Disease
- GSK Investigational Site, Chapel Hill
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ ከ18 እስከ 70 · ሁሉም ጾታዎች · የተሻሻለው በ3 ኦገስ 2026 · NCT06613698A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH
- GSK Investigational Site, Fayetteville
- GSK Investigational Site, Morehead City
ተሳታዮችን በመፈለግ ላይደረጃ 3
እድሜ ከ18 እስከ 75 · ሁሉም ጾታዎች · የተሻሻለው በ27 ጁላይ 2026 · NCT07221227A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH
- GSK Investigational Site, Fayetteville
- GSK Investigational Site, Wilson
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ ከ18 እስከ 75 · ሁሉም ጾታዎች · የተሻሻለው በ8 ጁላይ 2026 · NCT06920043Androgens and NAFLD Longitudinal Cohort Study
- Duke University, Durham
ተሳታዮችን በመፈለግ ላይየመመልከት ጥናት
እድሜ ከ18 እስከ 42 · ሴቶች · የተሻሻለው በ13 ኤፕሪ 2026 · NCT06124261Siemens Biomarker Multi-modality
- Duke University Medical Center, Durham
ተሳታዮችን በመፈለግ ላይ
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ3 ኤፕሪ 2026 · NCT07495332ከ ClinicalTrials.gov የተገኘ መረጃ፣ በ6 ኦክቶ 2026 የተሰብሰቡ። እያንዳንዱ ጥናት የራሱን ቅድመ ሁኔታ ይወስናል፤ የጥናት ቡድኑ ማን መሳተፍ እንደሚችል ይወስናል።